SCHEMBL25848928

SCHEMBL25848928

CNS(=O)(=O)c1ccc(C(=O)NCc2ccc(Br)cc2)s1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
TDP1 Q9NUW8 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.44
HDAC3 O15379 3/20 0.42
HDAC1 Q13547 3/20 0.42
HDAC4 P56524 2/20 0.42
HDAC6 Q9UBN7 2/20 0.42
POLB P06746 2/20 0.42
ATM Q13315 1/20 0.41
TGM2 P21980 1/20 0.40
AKT3 Q9Y243 1/20 0.40
KDM4E B2RXH2 1/20 0.40
APEX1 P27695 1/20 0.40
RECQL P46063 1/20 0.40
CHRM4 P08173 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25848775 0.88 MEN1 (0.52) KMT2AMEN1TDP1SMN1; SMN2KDM4E
SCHEMBL25848884 0.87 CCR1 (0.47) KMT2AMEN1TDP1SMN1; SMN2HDAC3
SCHEMBL25848782 0.85 KMT2A (0.49) CA1CA2KMT2AMEN1TDP1
SCHEMBL25848828 0.85 EPHX2 (0.53) CA1CA2KMT2AMEN1HDAC3
SCHEMBL25304098 0.84 EPHX2 (0.48) CA1CA2KMT2AMEN1TDP1
SCHEMBL25849324 0.84 PPARA (0.49) HDAC3HDAC1HDAC4HDAC6CHRM4
SCHEMBL25848805 0.83 USP5 (0.46) KMT2AMEN1TDP1SMN1; SMN2HDAC3
SCHEMBL25849354 0.83 KMT2A (0.40) KMT2AMEN1TDP1SMN1; SMN2HDAC3
SCHEMBL25848834 0.83 EPHX2 (0.49) SMN1; SMN2HDAC3HDAC1HDAC4HDAC6
SCHEMBL25848797 0.82 NR1H4 (0.50) HDAC3HDAC1HDAC4HDAC6POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219921-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2023-07-13 US disclosed
US-20230219921-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2023-07-13 US disclosed
EP-4175624-A1 KCNT1 INHIBITORS AND METHODS OF USE Praxis Precision Medicines, Inc. (US) 2023-05-10 EP disclosed
CN-116075297-A KCNT1 inhibitors and methods of use 普拉西斯精密医药公司 2023-05-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219921-A1 KCNT1 INHIBITORS AND METHODS OF USE KCNT1, KCNT2, KCNQ2 CA1 1505/4885CA2 624/4885KMT2A 232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.